MA27720A1 - Dérivés d'acide 3-(1-[3-(1,3-benzothiazole-6-yl)propylcarbamoyl]cycloalkyl)propano??que servant d'inhibiteurs de NEP - Google Patents
Dérivés d'acide 3-(1-[3-(1,3-benzothiazole-6-yl)propylcarbamoyl]cycloalkyl)propano??que servant d'inhibiteurs de NEPInfo
- Publication number
- MA27720A1 MA27720A1 MA28498A MA28498A MA27720A1 MA 27720 A1 MA27720 A1 MA 27720A1 MA 28498 A MA28498 A MA 28498A MA 28498 A MA28498 A MA 28498A MA 27720 A1 MA27720 A1 MA 27720A1
- Authority
- MA
- Morocco
- Prior art keywords
- disorder
- sexual
- dysfunction
- male
- female
- Prior art date
Links
- -1 1,3-benzothiazol-6-yl Chemical group 0.000 title 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title 1
- 125000000753 cycloalkyl group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000021663 Female sexual arousal disease Diseases 0.000 abstract 6
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 6
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 6
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 2
- 206010024419 Libido decreased Diseases 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- 208000027520 Somatoform disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000017020 hypoactive sexual desire disease Diseases 0.000 abstract 2
- 201000001881 impotence Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000027753 pain disease Diseases 0.000 abstract 2
- 230000001568 sexual effect Effects 0.000 abstract 2
- 208000017194 Affective disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010056340 Diabetic ulcer Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000007984 Female Infertility Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010020590 Hypercalciuria Diseases 0.000 abstract 1
- 206010021928 Infertility female Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000007466 Male Infertility Diseases 0.000 abstract 1
- 208000019255 Menstrual disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000004210 Pressure Ulcer Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000000558 Varicose Ulcer Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000027119 gastric acid secretion Effects 0.000 abstract 1
- 238000002513 implantation Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 201000011461 pre-eclampsia Diseases 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000001850 reproductive effect Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
Abstract
l'hypercalciurie, un ictus, le glaucome, l'obésité, des maladies métaboliques, le syndrome métabolique, le diabète, la tolérance entravée au glucose, la rétinopathie diabétique, la neuropathie diabétique, des troubles menstruels, l'accouchement avant terme, la pré-éclampsie, l'endométriose et des troubles de la reproduction, la stérilité masculine et la stérilité féminine, le syndrome d'ovaire polykystique, un défaut d'implantation, l'asthme, l'inflammation, la leucémie, la douleur, la douleur provoquée par un cancer, la dépression, la pharmacodépendance, la cirrhose, l'épilepsie, des troubles affectifs, la démence et la confusion gériatrique, des troubles gastro-intestinaux, la diarrhée, le syndrome du côlon irritable, la cicatrisation de plaies, les ulcères diabétiques et les ulcères veineux et les escarres de décubitus, le choc septique, la sécrétion d'acide gastrique, l'hyperréninémie, la fibrose kystique, une resténose, l'athérosclérose, un dysfonctionnement sexuel féminin (FSD), un trouble d'éveil sexuel, un trouble d'éveil sexuel féminin (FSAD), un dysfonctionnement sexuel masculin (MSD), un dysfonctionnement de l'érection masculine (MED), un trouble de désir sexuel hypoactif, un trouble orgasmique et un trouble douloureux sexuel. 13. Composé, méthode ou utilisation suivant la revendication 12, dans lequel le trouble ou l'affection est choisi entre un dysfonctionnement sexuel féminin (FSD), un trouble d'éveil sexuel, un trouble d'éveil sexuel féminin (FSAD), un dysfonctionnement sexuel masculin (MSD), un dysfonctionnement de l'érection masculine (MED), un trouble de désir sexuel hypoactif, un trouble orgasmique et un trouble douloureux sexuel. 14. Composé, méthode ou utilisation suivant la revendication 13, dans lequel le trouble ou l'affection est choisi entre un dysfonctionnement sexuel féminin (FSD), un trouble d'éveil sexuel féminin (FSAD), un dysfonctionnement sexuel masculin (MSD) et un dysfonctionnement, de l'érection masculine (MED).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0305916A GB0305916D0 (en) | 2003-03-14 | 2003-03-14 | New N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors |
| GB0329143A GB0329143D0 (en) | 2003-12-16 | 2003-12-16 | Novel pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27720A1 true MA27720A1 (fr) | 2006-01-02 |
Family
ID=32992599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28498A MA27720A1 (fr) | 2003-03-14 | 2005-09-14 | Dérivés d'acide 3-(1-[3-(1,3-benzothiazole-6-yl)propylcarbamoyl]cycloalkyl)propano??que servant d'inhibiteurs de NEP |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20040180941A1 (fr) |
| EP (1) | EP1606272A1 (fr) |
| JP (1) | JP3923512B2 (fr) |
| KR (1) | KR20050110003A (fr) |
| AP (1) | AP2005003393A0 (fr) |
| AR (1) | AR043551A1 (fr) |
| AU (1) | AU2004220269A1 (fr) |
| BR (1) | BRPI0408377A (fr) |
| CA (1) | CA2519072A1 (fr) |
| CL (1) | CL2004000512A1 (fr) |
| EA (1) | EA200501204A1 (fr) |
| EC (1) | ECSP056017A (fr) |
| HR (1) | HRP20050797A2 (fr) |
| IS (1) | IS8003A (fr) |
| MA (1) | MA27720A1 (fr) |
| MX (1) | MXPA05009788A (fr) |
| NL (1) | NL1025709C2 (fr) |
| NO (1) | NO20054169L (fr) |
| OA (1) | OA13039A (fr) |
| PA (1) | PA8597401A1 (fr) |
| PE (1) | PE20050310A1 (fr) |
| TN (1) | TNSN05227A1 (fr) |
| TW (1) | TW200504038A (fr) |
| UY (1) | UY28226A1 (fr) |
| WO (1) | WO2004080985A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007001348A (es) * | 2004-08-02 | 2008-03-11 | Bebaas Inc | Composiciones de vitamina b12. |
| WO2006027680A1 (fr) * | 2004-09-10 | 2006-03-16 | Pfizer Limited | Derives d'acide 3-(1-carbamoylcyclohexyl)propionique comme inhibiteurs de l'enzyme endopeptidase neutre |
| WO2006066361A1 (fr) | 2004-12-24 | 2006-06-29 | The University Of Queensland | Procede de traitement ou prophylaxie |
| AU2006275702A1 (en) | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel pharmaceutical compounds |
| US20130131007A1 (en) | 2005-09-07 | 2013-05-23 | Bebaas, Inc. | Vitamin b12 compositions |
| US20070178141A1 (en) * | 2005-09-07 | 2007-08-02 | Bebaas, Inc. | Vitamin B12 compositions |
| CA2866540A1 (fr) * | 2006-03-20 | 2007-09-27 | Spinifex Pharmaceuticals Pty Ltd. | Methode de traitement prophylactique ou therapeutique |
| EP2051696A2 (fr) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Compositions liquides stables de lévétiracétam et procédés |
| KR101177866B1 (ko) | 2011-03-24 | 2012-08-28 | 주식회사 케이엠더블유 | 케이블 접속 장치 |
| AU2019287549A1 (en) * | 2018-06-14 | 2021-01-28 | Astrazeneca Uk Limited | Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition |
| CN112955967A (zh) * | 2018-06-14 | 2021-06-11 | 阿斯利康(英国)有限公司 | 用cgmp特异性磷酸二酯酶5抑制剂医药组合物治疗勃起功能障碍的方法 |
| CA3113689A1 (fr) | 2018-09-25 | 2020-04-02 | Antabio Sas | Derives d'indane destines a etre utilises dans le traitement d'une infection bacterienne |
| IL292775A (en) * | 2019-11-08 | 2022-07-01 | Vella Bioscience Inc | preparations containing cannabidiol (cbd) that act peripherally and their use to improve female sexual function or to treat female sexual disorders |
| GB202402524D0 (en) * | 2024-02-22 | 2024-04-10 | Futura Medical Developments Ltd | Topical composition |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2503059A (en) * | 1950-04-04 | Nxchj | ||
| US2599000A (en) * | 1950-09-02 | 1952-06-03 | Smith Kline French Lab | Nu, nu-disubstituted-beta-halo-alkylamines |
| US3238215A (en) * | 1963-10-17 | 1966-03-01 | Sterling Drug Inc | 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines |
| IT1066857B (it) * | 1965-12-15 | 1985-03-12 | Acraf | Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione |
| US3511836A (en) * | 1967-12-13 | 1970-05-12 | Pfizer & Co C | 2,4,6,7-tetra substituted quinazolines |
| NL175059C (nl) * | 1974-02-23 | Boehringer Mannheim Gmbh | Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten. | |
| US4026894A (en) * | 1975-10-14 | 1977-05-31 | Abbott Laboratories | Antihypertensive agents |
| US4188390A (en) * | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
| FR2421888A1 (fr) * | 1978-02-06 | 1979-11-02 | Synthelabo | Amides d'alkylene-diamines et leur application en therapeutique |
| IT1094076B (it) * | 1978-04-18 | 1985-07-26 | Acraf | Cicloalchiltriazoli |
| JPS56110665A (en) * | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Sulfamoyl-substituted phenetylamine derivative and its preparation |
| DE3528032A1 (de) * | 1985-08-05 | 1987-02-05 | Hoechst Ag | Verfahren zur herstellung 2-substituierter benzthiazole |
| PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| AU4844396A (en) * | 1995-03-01 | 1996-09-18 | Kyowa Hakko Kogyo Co. Ltd. | Imidazoquinazoline derivatives |
| GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| US6037346A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| IL157009A0 (en) * | 2001-03-28 | 2004-02-08 | Pfizer | N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad |
-
2004
- 2004-03-08 PA PA20048597401A patent/PA8597401A1/es unknown
- 2004-03-09 WO PCT/IB2004/000822 patent/WO2004080985A1/fr not_active Ceased
- 2004-03-09 EA EA200501204A patent/EA200501204A1/ru unknown
- 2004-03-09 KR KR1020057017229A patent/KR20050110003A/ko not_active Ceased
- 2004-03-09 AP AP2005003393A patent/AP2005003393A0/xx unknown
- 2004-03-09 HR HR20050797A patent/HRP20050797A2/hr not_active Application Discontinuation
- 2004-03-09 MX MXPA05009788A patent/MXPA05009788A/es unknown
- 2004-03-09 EP EP04718706A patent/EP1606272A1/fr not_active Withdrawn
- 2004-03-09 AU AU2004220269A patent/AU2004220269A1/en not_active Abandoned
- 2004-03-09 JP JP2006500337A patent/JP3923512B2/ja not_active Expired - Fee Related
- 2004-03-09 BR BRPI0408377-6A patent/BRPI0408377A/pt not_active IP Right Cessation
- 2004-03-09 OA OA1200500261A patent/OA13039A/en unknown
- 2004-03-09 CA CA002519072A patent/CA2519072A1/fr not_active Abandoned
- 2004-03-10 PE PE2004000259A patent/PE20050310A1/es not_active Application Discontinuation
- 2004-03-11 AR ARP040100785A patent/AR043551A1/es unknown
- 2004-03-11 UY UY28226A patent/UY28226A1/es not_active Application Discontinuation
- 2004-03-12 NL NL1025709A patent/NL1025709C2/nl not_active IP Right Cessation
- 2004-03-12 TW TW093106666A patent/TW200504038A/zh unknown
- 2004-03-12 CL CL200400512A patent/CL2004000512A1/es unknown
- 2004-03-12 US US10/800,065 patent/US20040180941A1/en not_active Abandoned
-
2005
- 2005-08-29 IS IS8003A patent/IS8003A/is unknown
- 2005-09-07 NO NO20054169A patent/NO20054169L/no not_active Application Discontinuation
- 2005-09-14 MA MA28498A patent/MA27720A1/fr unknown
- 2005-09-14 EC EC2005006017A patent/ECSP056017A/es unknown
- 2005-09-14 TN TNP2005000227A patent/TNSN05227A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200504038A (en) | 2005-02-01 |
| NO20054169L (no) | 2005-12-07 |
| CA2519072A1 (fr) | 2004-09-23 |
| AU2004220269A1 (en) | 2004-09-23 |
| NL1025709C2 (nl) | 2005-03-14 |
| HRP20050797A2 (en) | 2006-02-28 |
| PA8597401A1 (es) | 2005-05-24 |
| NO20054169D0 (no) | 2005-09-07 |
| JP2006526572A (ja) | 2006-11-24 |
| EA200501204A1 (ru) | 2006-06-30 |
| PE20050310A1 (es) | 2005-05-04 |
| TNSN05227A1 (fr) | 2007-06-11 |
| NL1025709A1 (nl) | 2004-09-16 |
| JP3923512B2 (ja) | 2007-06-06 |
| EP1606272A1 (fr) | 2005-12-21 |
| OA13039A (en) | 2006-11-10 |
| BRPI0408377A (pt) | 2006-03-21 |
| IS8003A (is) | 2005-08-29 |
| CL2004000512A1 (es) | 2005-01-21 |
| ECSP056017A (es) | 2006-01-27 |
| WO2004080985A1 (fr) | 2004-09-23 |
| AR043551A1 (es) | 2005-08-03 |
| AP2005003393A0 (en) | 2005-09-30 |
| KR20050110003A (ko) | 2005-11-22 |
| MXPA05009788A (es) | 2005-10-26 |
| US20040180941A1 (en) | 2004-09-16 |
| UY28226A1 (es) | 2004-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27720A1 (fr) | Dérivés d'acide 3-(1-[3-(1,3-benzothiazole-6-yl)propylcarbamoyl]cycloalkyl)propano??que servant d'inhibiteurs de NEP | |
| CN1196483C (zh) | 提高生育力的组合物 | |
| NO151320B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktiv pyrrolidylmetyl-2-metoksy-4-amino-5-isopropyl-sulfonylbenzamider | |
| NO168795B (no) | Fiberoptisk undervannsledning for telekommunikasjonsformaal | |
| DE1909180A1 (de) | Disubstituierte N-Aminoindolinverbindungen und Verfahren zu ihrer Herstellung | |
| IL39304A (en) | A process for making vincamine and its analogues | |
| NO153001B (no) | Drivanordning for skip | |
| JP2003505380A5 (fr) | ||
| EP0422051A1 (fr) | Derives de 3-oxo-propane-nitrile de pyrazole condenses et procede servant a leur preparation | |
| NZ243013A (en) | ((arylalkylpiperidin-4-yl)methyl)-2a,3,4,5-tetrahydro-1(2h)-acenaphthylen-1- one derivatives and pharmaceutical compositions thereof | |
| MXPA03009259A (es) | Polimorfos de clorhidrato de fexofenadina. | |
| CN100338069C (zh) | 制备奥氮平及其中间体的方法 | |
| NO772752L (no) | Fremgangsm}te for fremstilling av 1,5-disubstituerte 2-pyrrolidioner | |
| US3853872A (en) | 2,3,4,5-substituted thiazoles | |
| WO1994024093A1 (fr) | Composes aminooxy cycliques inhibiteurs de la decarboxylase d'ornithine | |
| FI81788C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara fenotiazinfoereningar. | |
| DE69814420T2 (de) | Stereoselektive verfahren zur herstellung von gabapentinanalogen | |
| JPH0762018B2 (ja) | ジヒドロピリジンラクト−ル類 | |
| US6369218B1 (en) | Isomerisation of 6β-fluorosteroids into the corresponding 6α-fluoro derivatives | |
| SU1657062A3 (ru) | Способ получени производных 2-тиазолидинона | |
| US3209026A (en) | Cyclohexyloxycyclopropylamines | |
| TWD237425S (zh) | 具點滴吊架之助行器 | |
| TWD237426S (zh) | 具點滴吊架之助行器 | |
| Ikeda et al. | Preparation of Imidazo [2, 1-b] Thiazoles and Thiazolo [3, 2-a]-Benzimidazoles Using S-Ethenylsulfilimines | |
| US4593030A (en) | Use of 6-aryluracils as antiinflammatory and antiarthritic agents |